

Psychiatric Genomics, Inc.

[View the current Psychiatric Genomics, Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/28824-Psychiatric+Genomics%2C+Inc..html)

(<http://www.bioportfolio.com/bi corporate/28824-Psychiatric+Genomics%2C+Inc..html>)

Contact Details:

19 Firstfield Rd.

Gaithersburg

Maryland

20878

United States of America

Tel: 301.556.1300

Fax: 301.556.1350

Email: mail@psygenomics.com

Dr. C. Anthony Altar is President and Chief Scientific Officer at Psychiatric Genomics. His research team is responsible for gene discovery, medicinal chemistry, and drug discovery efforts. Dr. Altar has published 120 articles in peer-reviewed journals that include Science, Nature, PNAS, and the Burger's Medicinal Chemistry series. He pioneered methods for receptor localization using computerized image analysis and discovered the serotonin/ dopamine receptor binding patterns of antipsychotic drugs, which typify the atypical antipsychotics now in use. His team at Regeneron identified brain actions of neurotrophic factors, including roles in human depression, now an experimental clinical approach. As Director for Global Neuroscience Research at Otsuka America Pharmaceuticals, Dr. Altar led the team that discovered and co-developed aripiprazole (Abilify), recently FDA-approved.

Press Releases on Psychiatric Genomics, Inc.:

<p>Reportlinker Adds Bioinformatics - A Global Market Intelligence Report</p>	<p>17th November, 2009</p>	<p>Reportlinker</p>	<p>NEW YORK, Nov. 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. <i>Bioinformatics - A Global Market Intelligence Report</i> http://www</p>
<p>Largest Gene Study of Childhood IBD Finds 5 New Genes</p>	<p>16th November, 2009</p>	<p>The Children's Hospital of Philadelphia</p>	<p>--Findings Linked to a Key Molecule Active in GI Inflammation-- PHILADELPHIA, Nov. 16 /PRNewswire-USNewswire/ -- In the largest, most comprehensive genetic analysis of childhood-onset inflammatory</p>

Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants	16th November, 2009	Shire plc	PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)	16th November, 2009		INGELHEIM, Germany, November 16 /PRNewswire/ -- Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number of
Individuals May Feel More Anxiety During the Holidays Than in Previous Years	12th November, 2009	Remuda Ranch Programs for Eating and Anxiety Disorders	-- Seek help when things are stressful. Just talking about it with someone you trust helps. About Remuda Ranch Programs for Eating and Anxiety Disorders Remuda Ranch offers Christian

Psychiatric Genomics, Inc. Patents:



- 7132287- [Method for neural stem cell differentiation using 5HT-1A agonists](#)
- 7132286- [Method for neural stem cell differentiation using valproate](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast

service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

